A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers and Patients with Atopic Dermatitis
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs ATTO 1310 (Primary) ; ATTO 1310 (Primary)
- Indications Atopic dermatitis; Pruritus
- Focus Adverse reactions; First in man
- Sponsors Attovia Therapeutics
- 29 Jan 2025 New trial record
- 23 Jan 2025 According to the Attovia Therapeutics the Media Release, first subject has been dosed in a first-in-human Phase 1 study.